BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9748737)

  • 1. [Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis].
    Bláha V; Zadák Z; Bláha M; Havel E; Solichová D; Brátová M; Malý J; Kmonícek L
    Cas Lek Cesk; 1998 Jul; 137(14):424-9. PubMed ID: 9748737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
    Thiery J; Seidel D
    Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods].
    Bláha V; Havel E; Zadák Z; Pidrman V; Bláha M; Kalinová M
    Vnitr Lek; 1995 Oct; 41(10):724-9. PubMed ID: 8578708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Schneidewind JM; Latza R
    ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis.
    Mol MJ; Stalenhoef AF
    Neth J Med; 1990 Jun; 36(5-6):279-87. PubMed ID: 2395495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracorporeal treatment of hypercholesterolaemia.
    Olbricht CJ
    Nephrol Dial Transplant; 1993; 8(9):814-20. PubMed ID: 8255513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apheresis in severe hypercholesterolaemia].
    Graesdal A; Hovland A; Bjørbaek E
    Tidsskr Nor Laegeforen; 2004 Apr; 124(8):1085-7. PubMed ID: 15114383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Coronary revascularization with reduction of serum cholesterol level using LDL apheresis in patient with homozygous familial hypercholesterolemia].
    Takahashi T; Ihara K; Matsumiya G; Mizutani S; Hasegawa J; Sato S; Nakamura T; Kawamoto T; Nagai Y; Arai T
    Kokyu To Junkan; 1990 Sep; 38(9):925-30. PubMed ID: 2236967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term effect of LDL apheresis on coronary heart disease.
    Donner MG; Richter WO; Schwandt P
    Eur J Med Res; 1997 Jun; 2(6):270-4. PubMed ID: 9182655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.
    Jansen M; Gabriel H; Banyai S; Pidlich J; Weidinger F; Hörl WH; Derfler K
    Wien Klin Wochenschr; 1996; 108(14):425-31. PubMed ID: 8784984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of homozygous familial hypercholesterolemia with LDL-apheresis on a 4-year-old child].
    Lefort B; Giraud C; Saulnier JP; Bott L; Gambert C; Sosner P; Hankard R
    Arch Pediatr; 2009 Dec; 16(12):1554-8. PubMed ID: 19766469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
    Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
    J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reducing low density lipoprotein-cholesterol levels by apheresis].
    Reiber I; Gógl A
    Orv Hetil; 1994 Mar; 135(11):563-8. PubMed ID: 8159408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive lipid lowering treatment in coronary atherosclerosis.
    Stalenhoef AF; Kroon AA; Aengevaeren WR
    Cardiologia; 1997 Sep; 42(9):935-40. PubMed ID: 9369038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological efficacy of LDL apheresis in major hypercholesterolemia].
    Dairou F; Assogba U; Bruckert E; De Gennes JL; Turpin G
    Ann Med Interne (Paris); 1994; 145(5):328-32. PubMed ID: 7985942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different inflammatory responses induced by three LDL-lowering apheresis columns.
    Hovland A; Hardersen R; Sexton J; Mollnes TE; Lappegård KT
    J Clin Apher; 2009; 24(6):247-53. PubMed ID: 19927364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia.
    Hudgins LC; Kleinman B; Scheuer A; White S; Gordon BR
    Am J Cardiol; 2008 Nov; 102(9):1199-204. PubMed ID: 18940291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
    Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
    Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.